Abstract
Background: Dyslipidemia is one of the world's most prevalent & fatal diseases. Curcumin is an herbal remedy that may help improve dyslipidemia patterns. Some studies investigated the role of curcumin as a potential adjunct therapy in the management of dyslipidemia; the outcomes of such studies were conflicting.
Objectives: This study was conducted to assess the outcomes of curcumin supplementation with statin therapy on dyslipidemia patients attending a Family Medicine Center in Ismailia, Egypt.
Methodology: This study was conducted as a double-blind, randomized placebo-controlled trial. A total of 118 patients with dyslipidemia profiles at high risk were randomly assigned to two groups; an intervention group that received 1 g curcumin capsule once daily and a control group that received a placebo capsule of 1 g starch powder once daily, in addition to the statin drug (atorvastatin 40 mg) that was prescribed to all participants. The outcomes were assessed at baseline, 6 weeks, and 12 weeks.
Results: When compared to the placebo group, the curcumin group showed a significant reduction in both LDL-C and total cholesterol. In the mixed ANOVA analysis results, the time component of the study had a larger effect size for all participants than the interaction between time and group of intervention.
Conclusion: According to the study's findings, curcumin reduced LDL-C and total cholesterol in a statistically significant manner when added to high-intensity statin medication. It is necessary to conduct more research to determine curcumin's exact effect in patients with lipid profiles at low and moderate risk